N-propargylglycine restores survival by preventing calcium oxalate stone formation, tubular injury, and kidney dysfunction in a lethal mouse model of primary hyperoxaluria type 2 doi.org/10.1016/j.kint.2026.02.024 #MedSky #NephSky #OpenAccess

📢 The FDA has approved the first ever treatment for FSGS, supported by the PARASOL initiative. RaDaR contributed as an external validation cohort, highlighting the power of global collaboration & patient data. 📰: https://ow.ly/IJNH50YJXBB #RareDisease #KidneyResearch #FSGS

#NephMadness 2026 Really enjoyed this year’s writeups.. thoughtful and high-yield 👏 There’s a clear shift in nephrology: from broad immunosuppression → more targeted therapies. Still learning the ropes, but this was fun 🙂 Curious to see which direction the panel leans 👀 #NephMadnessNewbie

#NephMadness 2026: The PodCrawl Featuring these podcasts: - GN in Ten @isgd.bsky.social - Global Kidney Care @theisn.org - @freelyfiltered.bsky.social - @febrilepodcast.com - Kidney Commute @nkf-professionals.bsky.social - @coreimpodcast.bsky.social - Nephron Segment bit.ly/NM26Podcrawl

⏰ Just a few hours left to submit your #NephMadness 2026 bracket! The fun of #NephMadness is making your prediction on which team will become the 2026 Champion. Already submitted one? Disagreed with the group? Submit a back-up bracket: bit.ly/2DvWyou

Also see this study from India in @kireports.bsky.social Is there somethung special about targeted release $$$ vs enteric coated $ budesonide? bsky.app/profile/hswa... #ISNWCN

Hi, I’m Sruthi, Nephrologist from Kerala, India. I’m into clinical medicine, research, and lately curious about AI. Outside work, I enjoy time with family, art, and real conversations. Here to learn, connect, and grow 🙂 #Nephsky #Nephbluesky #Medsky